188 related articles for article (PubMed ID: 22541066)
1. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
2. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Kunos CA; Radivoyevitch T; Pink J; Chiu SM; Stefan T; Jacobberger J; Kinsella TJ
Radiat Res; 2010 Nov; 174(5):574-81. PubMed ID: 20954859
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA; Waggoner S; von Gruenigen V; Eldermire E; Pink J; Dowlati A; Kinsella TJ
Clin Cancer Res; 2010 Feb; 16(4):1298-306. PubMed ID: 20145183
[TBL] [Abstract][Full Text] [Related]
4. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.
Kunos CA; Colussi VC; Pink J; Radivoyevitch T; Oleinick NL
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1198-204. PubMed ID: 21470790
[TBL] [Abstract][Full Text] [Related]
6. Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.
Plamthottam S; Sun D; Van Valkenburgh J; Valenzuela J; Ruehle B; Steele D; Poddar S; Marshalik M; Hernandez S; Radu CG; Zink JI
J Biol Inorg Chem; 2019 Aug; 24(5):621-632. PubMed ID: 31250199
[TBL] [Abstract][Full Text] [Related]
7. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.
Kunos CA; Chiu SM; Pink J; Kinsella TJ
Radiat Res; 2009 Dec; 172(6):666-76. PubMed ID: 19929413
[TBL] [Abstract][Full Text] [Related]
8. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.
Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC
Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929
[TBL] [Abstract][Full Text] [Related]
10. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
11. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
[TBL] [Abstract][Full Text] [Related]
13. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
Popović-Bijelić A; Kowol CR; Lind ME; Luo J; Himo F; Enyedy EA; Arion VB; Gräslund A
J Inorg Biochem; 2011 Nov; 105(11):1422-31. PubMed ID: 21955844
[TBL] [Abstract][Full Text] [Related]
14. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
16. DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2).
Chen CW; Li Y; Hu S; Zhou W; Meng Y; Li Z; Zhang Y; Sun J; Bo Z; DePamphilis ML; Yen Y; Han Z; Zhu W
Oncogene; 2019 Mar; 38(13):2364-2379. PubMed ID: 30518875
[TBL] [Abstract][Full Text] [Related]
17. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
19. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
20. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
